Compare OGN & FOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OGN | FOR |
|---|---|---|
| Founded | 1923 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2020 | 2007 |
| Metric | OGN | FOR |
|---|---|---|
| Price | $13.68 | $27.06 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 3 |
| Target Price | $11.40 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 3.1M | 105.4K |
| Earning Date | 05-07-2026 | 04-21-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.95 | ★ 1.63 |
| Revenue | ★ $6,216,000,000.00 | $1,662,400,000.00 |
| Revenue This Year | $0.45 | $0.34 |
| Revenue Next Year | $1.67 | $7.73 |
| P/E Ratio | ★ $14.38 | $16.53 |
| Revenue Growth | N/A | ★ 10.14 |
| 52 Week Low | $5.69 | $22.81 |
| 52 Week High | $13.79 | $32.06 |
| Indicator | OGN | FOR |
|---|---|---|
| Relative Strength Index (RSI) | 45.85 | 38.32 |
| Support Level | $13.46 | $26.01 |
| Resistance Level | $13.79 | $27.87 |
| Average True Range (ATR) | 0.03 | 0.66 |
| MACD | -0.02 | -0.12 |
| Stochastic Oscillator | 19.35 | 23.98 |
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. The company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.